What Does the MERIT Stem Cell Stroke Trial Tell Us?

If you or someone close to you has had an ischemic stroke, it is natural to ask whether stem cells could help the brain recover. The harder question is not whether the idea is interesting, but whether the evidence is mature enough to justify treatment or travel. This new phase 1 trial is useful because it looks first at safety, not promises.

What did the MERIT researchers actually test?

The MERIT trial studied intravenous human umbilical cord-derived mesenchymal stem cells, often shortened to UC-MSCs, in people recovering from ischemic stroke ¹. Ischemic stroke means a blood vessel blockage has injured part of the brain. The trial enrolled 18 adults in the subacute period after stroke, which is a stage when recovery may still be changing naturally and rehabilitation is usually active.

The patients had moderate neurological symptoms by the National Institutes of Health Stroke Scale, or NIHSS. The median NIHSS score at the start was 9, with an interquartile range of 8 to 12. In plain English, this was not a study of people with only very mild symptoms, but it was also not a large trial across all stroke severities.

Everyone in the study received donor umbilical cord MSCs by intravenous infusion. The researchers used three escalating treatment groups and followed participants for 24 weeks. The main question was safety and tolerability: could this treatment be given without unacceptable side effects? The trial also looked secondarily at early signals of benefit and exploratory immune changes, but those were not the main proof target.

This matters because different stem cell sources are not interchangeable. If you are comparing donor cells with cells taken from your own body, our guide to autologous vs allogeneic stem cells gives useful background.

What did they find after 24 weeks?

The clearest finding was safety-related: the abstract reports no serious adverse events during follow-up ¹. Possible treatment-related adverse events included dizziness, nausea, sweating, fatigue, and epilepsy. The abstract does not prove that every listed event was caused by the cells, but it does show what the investigators were watching for.

The main recovery signal was that 14 of the 18 patients had a reduction in NIHSS score of 1 to 5 points during follow-up. NIHSS is a clinician-rated stroke scale; lower scores usually mean fewer measured neurological deficits. That sounds encouraging, but it should be read carefully. In subacute stroke, some improvement can happen because of natural healing, rehabilitation, better medical stability, and time.

So the honest summary is this: in this small group, intravenous UC-MSC treatment appeared tolerable over 24 weeks, and many patients improved on a stroke score. What the trial cannot show is whether the cells caused that improvement.

How strong is this evidence?

This is early clinical evidence. It was a phase 1, open-label, single-arm trial. That means all participants knew they were receiving the treatment, there was no placebo group, and there was no untreated comparison group.

Those design choices are common in first-in-human or early safety studies, but they limit what patients should conclude. With only 18 people, the study is too small to detect uncommon risks reliably. With no control group, it cannot separate a treatment effect from normal post-stroke recovery, rehabilitation, motivation, clinical attention, or measurement variation.

The follow-up period of 24 weeks is useful, but it is still not the same as long-term evidence. Stroke recovery can continue over months, and late safety signals may require larger and longer studies. The abstract also cannot answer practical questions many patients care about, such as which patients are most suitable, how treatment interacts with standard stroke medication, and whether one cell strategy is better than another.

So the strength of the paper is fairly specific: it supports the idea that this approach was feasible and reasonably tolerated in a small, monitored group. It does not establish effectiveness.

What could this mean if you are considering treatment?

For a prospective patient, the MERIT trial is a reason to ask better questions, not a reason to expect a dramatic result. It suggests that intravenous UC-MSCs for subacute ischemic stroke can be studied in humans under a formal trial protocol. That is different from proving that a clinic treatment will restore movement, speech, memory, or independence.

If you are weighing travel, the most important step is still a careful medical review. Stroke care often involves neurologists, rehabilitation physicians, blood pressure control, clot-prevention medication, mobility planning, swallowing assessment, and fall-risk management. Any regenerative treatment should be considered around that core care, not as a replacement for it.

It is also worth asking whether your situation resembles the people in the trial. Timing after stroke, stroke severity, other medical conditions, seizure history, medications, and travel fitness all matter. Our broader article on what stem cells can and cannot do may help frame those expectations before you speak with a physician.

This article is not personalised medical advice. It is a plain-English reading of one early trial so you can discuss the idea more clearly with a qualified clinician.

What we see at the clinic

In Pattaya, our physicians are often asked whether a stroke deficit that has stopped improving might respond to IV stem cells, and whether donor umbilical cord cells are safer or stronger than a patient’s own cells. We also see practical questions about how a neurologist’s report is reviewed, what monitoring is needed, and how any treatment would fit around rehabilitation, blood thinners, seizure risk, and travel plans.

Common questions

Does this trial prove stem cells improve stroke recovery? No. It shows a safety-focused early trial with encouraging but uncontrolled recovery signals, so it cannot prove cause and effect.

Were umbilical cord MSCs safe in this study? In the 18 participants followed for 24 weeks, the abstract reported no serious adverse events. The study was still too small to rule out rare or longer-term risks.

Should I travel for UC-MSC treatment after a stroke? That decision should not be based on one phase 1 trial. A neurologist and regenerative-medicine physician should review your stroke type, timing, medicines, seizure risk, rehabilitation needs, and fitness to travel.

Source

Cui L, Xiao M, Zhang Q, Liu H, Ren Y, Ma G, Zhou D, Ma Q, Yao H, Lin M, Gao D, Ye L, Wang R, Wang Y, Zhang L, Zhong L, Gao G, Chen J, Jolkkonen J, Boltze J, Hao J. Intravenous human umbilical cord-derived mesenchymal stem cell transplantation for ischemic stroke (MERIT): A phase 1 trial. Published May 28, 2026. DOI: https://doi.org/10.1016/j.xcrm.2026.102836

Key takeaway

The MERIT trial is an early, safety-first signal, not a treatment verdict. It suggests intravenous UC-MSCs were tolerated in a small subacute stroke group over 24 weeks, but it cannot show that the cells caused recovery. For now, expectations should stay modest: ask detailed safety questions, keep rehabilitation central, and treat efficacy claims as unproven.